Patents by Inventor John E. Cochran

John E. Cochran has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240122510
    Abstract: Blood sample optimization systems and methods are described that reduce or eliminate contaminates in collected blood samples, which in turn reduces or eliminates false positive readings in blood cultures or other testing of collected blood samples. A blood sample optimization system can include a blood sequestration device located between a patient needle and a sample needle. The blood sequestration device can include a sequestration chamber for sequestering an initial, potentially contaminated aliquot of blood, and may further include a sampling channel that bypasses the sequestration chamber to convey likely uncontaminated blood between the patient needle and the sample needle after the initial aliquot of blood is sequestered in the sequestration chamber.
    Type: Application
    Filed: May 15, 2023
    Publication date: April 18, 2024
    Applicant: KURIN, INC.
    Inventors: Bobby E. ROGERS, Gino KANG, David Karl STROUP, Jonas Dean COCHRAN, Arthur DEPTALA, John DETLOFF, Lonnie POGUE, Brian MACOWSKI
  • Patent number: 11866446
    Abstract: The disclosure provides at least one entity chosen from compounds of Formula I, a tautomer thereof, a deuterated derivative of that compound or tautomer, and a pharmaceutically acceptable salt of any of the foregoing, compositions comprising the same, and methods of using the same, including uses in treating APOL1-mediated diseases, including pancreatic cancer, focal segmental glomerulosclerosis (FSGS), and/or non-diabetic kidney disease (NDKD).
    Type: Grant
    Filed: August 26, 2021
    Date of Patent: January 9, 2024
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Jun Myun Ahn, Samantha Angle, Michael Aaron Brodney, Jingrong Cao, John E. Cochran, Jon H. Come, Leslie A. Dakin, Elena Dolgikh, Brad D. Maxwell, Suganthini S. Nanthakumar, Hardwin O'Dowd, Jessica Howard Olsen, Timothy J. Senter, Akira Joseph Shimizu, Steven David Stone, Haoxuan Wang
  • Publication number: 20230399343
    Abstract: The disclosure provides processes for synthesizing Compound I, and pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: January 4, 2023
    Publication date: December 14, 2023
    Inventors: Paul Angell, John E. Cochran, Benjamin J. Littler, David Siesel, Armando Urbina, Corey Don Anderson, Jeremy J. Clemens, Thomas Cleveland, Timothy Richard Coon, Bryan Frieman, Peter Grootenhuis, Sara Sabina Hadida Ruah, Jason McCartney, Mark Thomas Miller, Prasuna Paraselli, Fabrice Pierre, Sara E. Swift, Jinglan Zhou
  • Patent number: 11584761
    Abstract: The disclosure provides processes for synthesizing Compound I, and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: August 13, 2020
    Date of Patent: February 21, 2023
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Paul Angell, John E. Cochran, Benjamin J. Littler, David Siesel, Armando Urbina, Corey Don Anderson, Jeremy J. Clemens, Thomas Cleveland, Timothy Richard Coon, Bryan Frieman, Peter Grootenhuis, Sara Sabina Hadida Ruah, Jason McCartney, Mark Thomas Miller, Prasuna Paraselli, Fabrice Pierre, Sara E. Swift, Jinglan Zhou
  • Publication number: 20220106327
    Abstract: The disclosure provides at least one entity chosen from compounds of Formula I, a tautomer thereof, a deuterated derivative of that compound or tautomer, and a pharmaceutically acceptable salt of any of the foregoing, compositions comprising the same, and methods of using the same, including uses in treating APOL1-mediated diseases, including pancreatic cancer, focal segmental glomerulosclerosis (FSGS), and/or non-diabetic kidney disease (NDKD).
    Type: Application
    Filed: August 26, 2021
    Publication date: April 7, 2022
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Jun Myun AHN, Samantha ANGLE, Michael Aaron BRODNEY, Jingrong CAO, John E. COCHRAN, Jon H. COME, Leslie A. DAKIN, Elena DOLGIKH, Brad D. MAXWELL, Suganthini S. NANTHAKUMAR, Hardwin O'DOWD, Jessica Howard OLSEN, Timothy J. SENTER, Akira Joseph SHIMIZU, Steven David STONE, Haoxuan WANG
  • Publication number: 20210047345
    Abstract: The disclosure provides processes for synthesizing Compound I, and pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: August 13, 2020
    Publication date: February 18, 2021
    Inventors: Paul Angell, John E. Cochran, Benjamin J. Littler, David Siesel, Armando Urbina, Corey Don Anderson, Jeremy J. Clemens, Thomas Cleveland, Timothy Richard Coon, Bryan Frieman, Peter Grootenhuis, Sara Sabina Hadida Ruah, Jason McCartney, Mark Thomas Miller, Prasuna Paraselli, Fabrice Pierre, Sara E. Swift, Jinglan Zhou
  • Patent number: 8871904
    Abstract: The invention relates to compounds and processes useful for the preparation of protease inhibitors, particularly serine protease inhibitors. The protease inhibitors are useful for treatment of HCV infections.
    Type: Grant
    Filed: February 14, 2013
    Date of Patent: October 28, 2014
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Gerald J. Tanoury, Minzhang Chen, John E. Cochran, Adam Looker, Valdas Jurkauskas
  • Publication number: 20140107318
    Abstract: The invention relates to compounds and processes useful for the preparation of protease inhibitors, particularly serine protease inhibitors. The protease inhibitors are useful for treatment of HCV infections.
    Type: Application
    Filed: December 17, 2013
    Publication date: April 17, 2014
    Applicant: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Gerald J. Tanoury, Minzhang Chen, John E. Cochran, Valdas Jurkauskas
  • Patent number: 8637457
    Abstract: The invention relates to compounds and processes useful for the preparation of protease inhibitors, particularly serine protease inhibitors. The protease inhibitors are useful for treatment of HCV infections.
    Type: Grant
    Filed: March 15, 2010
    Date of Patent: January 28, 2014
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Gerald J. Tanoury, Minzhang Chen, John E. Cochran, Valdas Jurkauskas
  • Patent number: 8399615
    Abstract: The invention relates to compounds and processes useful for the preparation of protease inhibitors, particularly serine protease inhibitors. The protease inhibitors are useful for treatment of HCV infections.
    Type: Grant
    Filed: April 27, 2009
    Date of Patent: March 19, 2013
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Gerald J. Tanoury, Minzhang Chen, John E. Cochran, Adam Looker, Valdas Jurkauskas
  • Patent number: 8338412
    Abstract: The present invention relates to inhibitors of p38, a mammalian protein kinase involved cell proliferation, cell death and response to extracellular stimuli. The invention also relates to methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing those compositions in the treatment and prevention of various disorders.
    Type: Grant
    Filed: May 13, 2011
    Date of Patent: December 25, 2012
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Guy W. Bemis, Francesco G. Salituro, John P. Duffy, John E. Cochran, Edmund M. Harrington, Mark A. Murcko, Keith P. Wilson, Michael Su, Vincent P. Galullo
  • Publication number: 20110281878
    Abstract: The present invention relates to inhibitors of p38, a mammalian protein kinase involved cell proliferation, cell death and response to extracellular stimuli. The invention also relates to methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing those compositions in the treatment and prevention of various disorders.
    Type: Application
    Filed: May 13, 2011
    Publication date: November 17, 2011
    Applicant: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Guy W. Bemis, Francesco Gerald Salituro, John Patrick Duffy, John E. Cochran, Edmund Martin Harrington, Mark A. Murko, Keith P. Wilson, Michael Su, Vincent P. Galullo
  • Patent number: 7951809
    Abstract: The present invention relates to inhibitors of p38, a mammalian protein kinase involved cell proliferation, cell death and response to extracellular stimuli. The invention also relates to methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing those compositions in the treatment and prevention of various disorders.
    Type: Grant
    Filed: April 3, 2008
    Date of Patent: May 31, 2011
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Guy W. Bemis, Francesco G. Salituro, John P. Duffy, John E. Cochran, Edmund M. Harrington, Mark A. Murcko, Keith P. Wilson, Michael Su, Vincent P. Galullo
  • Patent number: 7776887
    Abstract: The invention relates to compounds and processes useful for the preparation of protease inhibitors, particularly serine protease inhibitors. The protease inhibitors are useful for treatment of HCV infections.
    Type: Grant
    Filed: August 18, 2006
    Date of Patent: August 17, 2010
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Gerald J. Tanoury, Minzhang Chen, John E. Cochran, Valdas Jurkauskas
  • Publication number: 20100174077
    Abstract: The invention relates to compounds and processes useful for the preparation of protease inhibitors, particularly serine protease inhibitors. The protease inhibitors are useful for treatment of HCV infections.
    Type: Application
    Filed: March 15, 2010
    Publication date: July 8, 2010
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Gerald J. Tanoury, Minzhang Chen, John E. Cochran, Valdas Jurkauskas
  • Publication number: 20100063252
    Abstract: The invention relates to compounds and processes useful for the preparation of protease inhibitors, particularly serine protease inhibitors. The protease inhibitors are useful for treatment of HCV infections.
    Type: Application
    Filed: April 27, 2009
    Publication date: March 11, 2010
    Inventors: Gerald J. Tanoury, Minzhang Chen, John E. Cochran, Adam Looker, Valdas Jurkauskas
  • Publication number: 20090203702
    Abstract: The present invention relates to inhibitors of p38, a mammalian protein kinase involved cell proliferation, cell death and response to extracellular stimuli. The invention also relates to methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing those compositions in the treatment and prevention of various disorders.
    Type: Application
    Filed: April 3, 2008
    Publication date: August 13, 2009
    Applicant: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Guy W. Bemis, Francesco Gerald Salituro, John Patrick Duffy, John E. Cochran, Edmund Martin Harrington, Mark A. Murcko, Keith P. Wilson, Michael Su, Vincent P. Galullo
  • Patent number: 7365072
    Abstract: The present invention relates to inhibitors of p38, a mammalian protein kinase involved cell proliferation, cell death and response to extracellular stimuli. The invention also relates to methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing those compositions in the treatment and prevention of various disorders.
    Type: Grant
    Filed: December 8, 2005
    Date of Patent: April 29, 2008
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Guy W Bemis, Francesco G Salituro, John P Duffy, John E Cochran, Edmund M Harrington, Mark A Murcko, Keith P Wilson, Michael Su, Vincent P Galullo
  • Patent number: 7271181
    Abstract: The present invention relates to inhibitors of p38, a mammalian protein kinase involved cell proliferation, cell death and response to extracellular stimuli. The invention also relates to methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing those compositions in the treatment and prevention of various disorders.
    Type: Grant
    Filed: May 10, 2002
    Date of Patent: September 18, 2007
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Jeremy Green, Scott L Harbeson, John E Cochran
  • Patent number: 7205305
    Abstract: The present invention relates to inhibitors of p38, a mammalian protein kinase involved cell proliferation, cell death and response to extracellular stimuli. The invention also relates to methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing those compositions in the treatment and prevention of various disorders.
    Type: Grant
    Filed: July 17, 2003
    Date of Patent: April 17, 2007
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Guy W Bemis, Francesco G Salituro, John P Duffy, John E Cochran, Edmund M Harrington, Mark A Murcko, Keith P Wilson, Michael Su, Vincent P Galullo